Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

Also called NCT06402851

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06402851
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06402851. Randomized; single masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
Acronym
VISIONAIRE
Condition
Atrium; Fibrillation
Condition
Chronic Kidney Diseases
Intervention (Drug)
Anticoagulant Oral
Lead sponsor
Hospital Sirio-Libanes (class: other)
Collaborator
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct06402851
Content hash
826238a91671ddb87282934495726631c183d4719a03b3b67fe55af25bd1e28b